Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (50587)	12/24/2018 8:48:44 AM
From: Art Bechhoefer	Respond to of 52153

GILD, IONS, ANIK Art

To: IRWIN JAMES FRANKEL who wrote (50587)	12/24/2018 9:45:28 AM
From: fred hayes	Read Replies (2) \| Respond to of 52153

Jim, I keep coming back to NVLN. 19 million shares around 90-some cents, say mc of $18 or $19 million. Current debt $412 million with $52 million cash for ev of around $380 million. Looks to me like reasonable expectations of at least $150 million in Myalept sales with 80 percent margins before considering label and market expansion. But debt due in 2019, market is pricing for bk. Seeking reorganization/buyout. But if fails, looks like debt holders wipe out equity holders…So wouldn't it be reasonable to expect a buyout here if someone with a little cash can verify sales potential? Should be worth at least 5x sales, minus debt, no? Look here for starters… https://ir.novelion.com/news-releases/news-release-details/novelion-therapeutics-subsidiary-enters-term-loan-agreement-and